<DOC>
	<DOCNO>NCT02037347</DOCNO>
	<brief_summary>To test ability palifermin ( recombinant human keratinocyte growth factor ) decrease mucocutaneous injury promote epithelial repair Toxic Epidermal Necrolysis Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis Overlap , diseases extensive slough skin mucosa , include eye , gastrointestinal tract , respiratory genitourinary system .</brief_summary>
	<brief_title>Study Evaluate Use Palifermin Treat Toxic Epidermal Necrolysis</brief_title>
	<detailed_description />
	<mesh_term>Stevens-Johnson Syndrome</mesh_term>
	<criteria>Skin biopsy early disease show apoptotic keratinocytes epidermis advanced disease necrosis entire epidermis Epidermal detachment erythematous purpuric macule involve 10 % body surface area addition involvement oropharynx ; may involvement mucosal surface , ie . conjunctiva , gastrointestinal tract , respiratory genitourinary epithelium Age 18 year old old The patient expect survive long 48 hour Skin detachment 90 % body surface area Skin detachment progress previous 48 hour A positive serum pregnancy test Age &lt; 18 year old Known hematologic solid organ malignancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>